185 related articles for article (PubMed ID: 25237354)
1. Comparison of the Effects of Enoxaparin and Heparin on Inflammatory Biomarkers in Patients with ST-segment Elevated Myocardial Infarction: A prospective Open Label Pilot Clinical Trial.
Nasiripour S; Gholami K; Mousavi S; Mohagheghi A; Radfar M; Abdollahi M; Khazaeipour Z; Mojtahedzadeh M
Iran J Pharm Res; 2014; 13(2):583-90. PubMed ID: 25237354
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
Auffret V; Leurent G; Boulmier D; Bedossa M; Zabalawi A; Hacot JP; Coudert I; Filippi E; Castellant P; Rialan A; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Le Guellec M; Gilard M; Le Breton H
Arch Cardiovasc Dis; 2016 Dec; 109(12):696-707. PubMed ID: 27818120
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory markers and cardiac function in acute coronary syndrome: difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models.
Di Stefano R; Di Bello V; Barsotti MC; Grigoratos C; Armani C; Dell'Omodarme M; Carpi A; Balbarini A
Biomed Pharmacother; 2009 Dec; 63(10):773-80. PubMed ID: 19906505
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention: a Pilot Study.
Gao CZ; Ma QQ; Wu J; Liu R; Wang F; Bai J; Yang XJ; Fu Q; Wei P
Cell Physiol Biochem; 2018; 48(1):385-396. PubMed ID: 30016801
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
[TBL] [Abstract][Full Text] [Related]
6. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Montalescot G; Zeymer U; Silvain J; Boulanger B; Cohen M; Goldstein P; Ecollan P; Combes X; Huber K; Pollack C; Bénezet JF; Stibbe O; Filippi E; Teiger E; Cayla G; Elhadad S; Adnet F; Chouihed T; Gallula S; Greffet A; Aout M; Collet JP; Vicaut E;
Lancet; 2011 Aug; 378(9792):693-703. PubMed ID: 21856483
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.
Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Santopinto J; Hecquet C; Vittori L;
Circulation; 2003 Oct; 108(16 Suppl 1):III14-21. PubMed ID: 14605015
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
Montalescot G; Bal-dit-Sollier C; Chibedi D; Collet JP; Soulat T; Dalby M; Choussat R; Cohen A; Slama M; Steg PG; Dubois-Randé JL; Metzger JP; Tarragano F; Guermonprez JL; Drouet L;
Am J Cardiol; 2003 Apr; 91(8):925-30. PubMed ID: 12686329
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin.
Silvain J; O'Connor SA; Yan Y; Kerneis M; Hauguel-Moreau M; Zeitouni M; Overtchouk P; Ankri A; Brugier D; Vicaut E; Ecollan P; Galier S; Collet JP; Montalescot G;
Am J Cardiovasc Drugs; 2018 Dec; 18(6):503-511. PubMed ID: 30144017
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
[TBL] [Abstract][Full Text] [Related]
11. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
[TBL] [Abstract][Full Text] [Related]
14. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
16. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Goodman SG; Fitchett D; Armstrong PW; Tan M; Langer A;
Circulation; 2003 Jan; 107(2):238-44. PubMed ID: 12538422
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction.
Chaudhuri A; Janicke D; Wilson MF; Tripathy D; Garg R; Bandyopadhyay A; Calieri J; Hoffmeyer D; Syed T; Ghanim H; Aljada A; Dandona P
Circulation; 2004 Feb; 109(7):849-54. PubMed ID: 14757687
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of inflammatory parameters pentraxin-3, cyclophilin and heparin-binding epidermal growth factor-like growth factor in patients with ST-elevation myocardial infarction.
Vuković Dejanović V; Bogavac-Stanojević N; Kotur Stevuljević J; Vukašinović A; Stefanović A; Kafedzic S; Zdravković M; Ilić I; Hinić S; Cerović M; Stefanović M; Spasojević-Kalimanovska V; Memon L; Nešković AN
Scand J Clin Lab Invest; 2020 Feb; 80(1):66-72. PubMed ID: 31799884
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome.
Jolly S; Tan M; Mendelsohn A; Fitchett D; Armstrong PW; Langer A; Goodman SG
Am J Cardiol; 2007 Jan; 99(2):186-8. PubMed ID: 17223416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
